22 May 2013
Keywords: promising, initial, ph, ii, data, ascenta, at-101
Article | 09 March 2009
The USA's Ascenta Therapeutics reported positive preliminary results
from a Phase II study of AT-101 in combination with docetaxel and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 March 2009
21 May 2013
© 2013 thepharmaletter.com